BIO-Europe Spring 2026

The Australian Advantage for Accelerated Start-Up
Take advantage of Australia’s regulatory environment, where biotech companies can initiate clinical trials without an IND, significantly reducing regulatory timelines by up to 12 months. On top of that, companies conducting early-phase clinical trials in Australia benefit from a 43.5% government rebate on clinical trial costs, making Australia an ideal location for early-stage studies.

Extensive Network and Proven Expertise
With access to over 2,000 clinical sites across the United States, and a strong operational presence in Asia and Europe, Avance Clinical excels in patient recruitment and trial management. Our dedicated in-house teams of experts ensure regulatory compliance and efficient project delivery, helping you achieve key milestones on time.

GlobalReady Program
Our GlobalReady program is designed to transition biotechs seamlessly from early-phase trials in Australia to multi-regional studies in North America, Asia, and Europe. This integrated, hands-on approach ensures global acceptance of clinical data, accelerates approvals, and reduces costs for our clients.

ClinicReady Program
The ClinicReady program ensures rapid trial initiation, backed by expert teams to guide your project through the early drug development phases, ensuring an efficient and timely start for your clinical trial.